[1]
Scarisbrick JJ, Quaglino P, Prince HM, Papadavid E, Hodak E, Bagot M, Servitje O, Berti E, Ortiz-Romero P, Stadler R, Patsatsi A, Knobler R, Guenova E, Child F, Whittaker S, Nikolaou V, Tomasini C, Amitay I, Prag Naveh H, Ram-Wolff C, Battistella M, Alberti-Violetti S, Stranzenbach R, Gargallo V, Muniesa C, Koletsa T, Jonak C, Porkert S, Mitteldorf C, Estrach T, Combalia A, Marschalko M, Csomor J, Szepesi A, Cozzio A, Dummer R, Pimpinelli N, Grandi V, Beylot-Barry M, Pham-Ledard A, Wobser M, Geissinger E, Wehkamp U, Weichenthal M, Cowan R, Parry E, Harris J, Wachsmuth R, Turner D, Bates A, Healy E, Trautinger F, Latzka J, Yoo J, Vydianath B, Amel-Kashipaz R, Marinos L, Oikonomidi A, Stratigos A, Vignon-Pennamen MD, Battistella M, Climent F, Gonzalez-Barca E, Georgiou E, Senetta R, Zinzani P, Vakeva L, Ranki A, Busschots AM, Hauben E, Bervoets A, Woei-A-Jin FJSH, Matin R, Collins G, Weatherhead S, Frew J, Bayne M, Dunnill G, McKay P, Arumainathan A, Azurdia R, Benstead K, Twigger R, Rieger K, Brown R, Sanches JA, Miyashiro D, Akilov O, McCann S, Sahi H, Damasco FM, Querfeld C, Folkes A, Bur C, Klemke CD, Enz P, Pujol R, Quint K, Geskin L, Hong E, Evison F, Vermeer M, Cerroni L, Kempf W, Kim Y, Willemze R. The PROCLIPI international registry of early-stage mycosis fungoides identifies substantial diagnostic delay in most patients. The British journal of dermatology. 2019 Aug:181(2):350-357. doi: 10.1111/bjd.17258. Epub 2018 Nov 25
[PubMed PMID: 30267549]
[2]
Su C, Tang R, Bai HX, Girardi M, Karakousis G, Zhang PJ, Xiao R, Zhang G. Disease site as a prognostic factor for mycosis fungoides: an analysis of 2428 cases from the US National Cancer Database. British journal of haematology. 2019 May:185(3):592-595. doi: 10.1111/bjh.15570. Epub 2018 Sep 14
[PubMed PMID: 30216417]
Level 3 (low-level) evidence
[3]
Prince HM, Querfeld C. Integrating novel systemic therapies for the treatment of mycosis fungoides and Sézary syndrome. Best practice & research. Clinical haematology. 2018 Sep:31(3):322-335. doi: 10.1016/j.beha.2018.07.007. Epub 2018 Jul 18
[PubMed PMID: 30213403]
[4]
Hossain C, Jennings T, Duffy R, Knoblauch K, Gochoco A, Chervoneva I, Shi W, Alpdogan SO, Porcu P, Pro B, Sahu J. The histological prevalence and clinical implications of folliculotropism and syringotropism in mycosis fungoides. Chinese clinical oncology. 2019 Feb:8(1):6. doi: 10.21037/cco.2018.10.02. Epub
[PubMed PMID: 30818957]
[5]
Lim HLJ, Tan EST, Tee SI, Ho ZY, Boey JJJ, Tan WP, Tang MBY, Shen L, Chan YH, Tan SH. Epidemiology and prognostic factors for mycosis fungoides and Sézary syndrome in a multi-ethnic Asian cohort: a 12-year review. Journal of the European Academy of Dermatology and Venereology : JEADV. 2019 Aug:33(8):1513-1521. doi: 10.1111/jdv.15526. Epub 2019 Mar 27
[PubMed PMID: 30801779]
[6]
Bergallo M, Daprà V, Fava P, Ponti R, Calvi C, Montanari P, Novelli M, Quaglino P, Galliano I, Fierro MT. DNA from Human Polyomaviruses, MWPyV, HPyV6, HPyV7, HPyV9 and HPyV12 in Cutaneous T-cell Lymphomas. Anticancer research. 2018 Jul:38(7):4111-4114. doi: 10.21873/anticanres.12701. Epub
[PubMed PMID: 29970537]
[7]
Väisänen E, Fu Y, Koskenmies S, Fyhrquist N, Wang Y, Keinonen A, Mäkisalo H, Väkevä L, Pitkänen S, Ranki A, Hedman K, Söderlund-Venermo M. Cutavirus DNA in Malignant and Nonmalignant Skin of Cutaneous T-Cell Lymphoma and Organ Transplant Patients but Not of Healthy Adults. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2019 May 17:68(11):1904-1910. doi: 10.1093/cid/ciy806. Epub
[PubMed PMID: 30239652]
[8]
Slodownik D, Moshe S, Sprecher E, Goldberg I. Occupational mycosis fungoides - a case series. International journal of dermatology. 2017 Jul:56(7):733-737. doi: 10.1111/ijd.13589. Epub 2017 Mar 3
[PubMed PMID: 28255994]
Level 2 (mid-level) evidence
[9]
Blaizot R, Ouattara E, Fauconneau A, Beylot-Barry M, Pham-Ledard A. Infectious events and associated risk factors in mycosis fungoides/Sézary syndrome: a retrospective cohort study. The British journal of dermatology. 2018 Dec:179(6):1322-1328. doi: 10.1111/bjd.17073. Epub 2018 Oct 12
[PubMed PMID: 30098016]
Level 2 (mid-level) evidence
[10]
Fujii K. New Therapies and Immunological Findings in Cutaneous T-Cell Lymphoma. Frontiers in oncology. 2018:8():198. doi: 10.3389/fonc.2018.00198. Epub 2018 Jun 4
[PubMed PMID: 29915722]
[11]
Amorim GM, Niemeyer-Corbellini JP, Quintella DC, Cuzzi T, Ramos-E-Silva M. Clinical and epidemiological profile of patients with early stage mycosis fungoides. Anais brasileiros de dermatologia. 2018 Jul-Aug:93(4):546-552. doi: 10.1590/abd1806-4841.20187106. Epub
[PubMed PMID: 30066762]
Level 2 (mid-level) evidence
[12]
Amorim GM, Niemeyer-Corbellini JP, Quintella DC, Cuzzi T, Ramos-E-Silva M. Hypopigmented mycosis fungoides: a 20-case retrospective series. International journal of dermatology. 2018 Mar:57(3):306-312. doi: 10.1111/ijd.13855. Epub 2018 Jan 10
[PubMed PMID: 29318586]
Level 2 (mid-level) evidence
[13]
Eder J, Rogojanu R, Jerney W, Erhart F, Dohnal A, Kitzwögerer M, Steiner G, Moser J, Trautinger F. Mast Cells Are Abundant in Primary Cutaneous T-Cell Lymphomas: Results from a Computer-Aided Quantitative Immunohistological Study. PloS one. 2016:11(11):e0163661. doi: 10.1371/journal.pone.0163661. Epub 2016 Nov 28
[PubMed PMID: 27893746]
[14]
Tardío JC, Arias D, Khedaoui R. Indeterminate Cell Histiocytosis and Mycosis Fungoides: A Hitherto Unreported Association. The American Journal of dermatopathology. 2019 Jun:41(6):461-463. doi: 10.1097/DAD.0000000000001154. Epub
[PubMed PMID: 30024412]
[15]
Yamashita T, Abbade LP, Marques ME, Marques SA. Mycosis fungoides and Sézary syndrome: clinical, histopathological and immunohistochemical review and update. Anais brasileiros de dermatologia. 2012 Nov-Dec:87(6):817-28; quiz 829-30
[PubMed PMID: 23197199]
[16]
Pimpinelli N, Olsen EA, Santucci M, Vonderheid E, Haeffner AC, Stevens S, Burg G, Cerroni L, Dreno B, Glusac E, Guitart J, Heald PW, Kempf W, Knobler R, Lessin S, Sander C, Smoller BS, Telang G, Whittaker S, Iwatsuki K, Obitz E, Takigawa M, Turner ML, Wood GS, International Society for Cutaneous Lymphoma. Defining early mycosis fungoides. Journal of the American Academy of Dermatology. 2005 Dec:53(6):1053-63
[PubMed PMID: 16310068]
[17]
Robson A. Immunocytochemistry and the diagnosis of cutaneous lymphoma. Histopathology. 2010 Jan:56(1):71-90. doi: 10.1111/j.1365-2559.2009.03457.x. Epub
[PubMed PMID: 20055906]
[18]
Burg G, Dummer R, Nestle FO, Doebbeling U, Haeffner A. Cutaneous lymphomas consist of a spectrum of nosologically different entities including mycosis fungoides and small plaque parapsoriasis. Archives of dermatology. 1996 May:132(5):567-72
[PubMed PMID: 8624155]
[19]
Keehn CA, Belongie IP, Shistik G, Fenske NA, Glass LF. The diagnosis, staging, and treatment options for mycosis fungoides. Cancer control : journal of the Moffitt Cancer Center. 2007 Apr:14(2):102-11
[PubMed PMID: 17387295]
[20]
Bowman PH, Hogan DJ, Sanusi ID. Mycosis fungoides bullosa: report of a case and review of the literature. Journal of the American Academy of Dermatology. 2001 Dec:45(6):934-9
[PubMed PMID: 11712043]
Level 3 (low-level) evidence
[21]
Georgala S, Katoulis AC, Symeonidou S, Georgala C, Vayopoulos G. Persistent pigmented purpuric eruption associated with mycosis fungoides: a case report and review of the literature. Journal of the European Academy of Dermatology and Venereology : JEADV. 2001 Jan:15(1):62-4
[PubMed PMID: 11451328]
Level 3 (low-level) evidence
[22]
Lindae ML, Abel EA, Hoppe RT, Wood GS. Poikilodermatous mycosis fungoides and atrophic large-plaque parapsoriasis exhibit similar abnormalities of T-cell antigen expression. Archives of dermatology. 1988 Mar:124(3):366-72
[PubMed PMID: 3257858]
[23]
Zelger B, Sepp N, Weyrer K, Grünewald K, Zelger B. Syringotropic cutaneous T-cell lymphoma: a variant of mycosis fungoides? The British journal of dermatology. 1994 Jun:130(6):765-9
[PubMed PMID: 8011503]
[24]
El-Shabrawi-Caelen L, Cerroni L, Medeiros LJ, McCalmont TH. Hypopigmented mycosis fungoides: frequent expression of a CD8+ T-cell phenotype. The American journal of surgical pathology. 2002 Apr:26(4):450-7
[PubMed PMID: 11914622]
[25]
Willemze R, Jaffe ES, Burg G, Cerroni L, Berti E, Swerdlow SH, Ralfkiaer E, Chimenti S, Diaz-Perez JL, Duncan LM, Grange F, Harris NL, Kempf W, Kerl H, Kurrer M, Knobler R, Pimpinelli N, Sander C, Santucci M, Sterry W, Vermeer MH, Wechsler J, Whittaker S, Meijer CJ. WHO-EORTC classification for cutaneous lymphomas. Blood. 2005 May 15:105(10):3768-85
[PubMed PMID: 15692063]
[26]
Lopez AT, Bates S, Geskin L. Current Status of HDAC Inhibitors in Cutaneous T-cell Lymphoma. American journal of clinical dermatology. 2018 Dec:19(6):805-819. doi: 10.1007/s40257-018-0380-7. Epub
[PubMed PMID: 30173294]
[27]
PDQ Adult Treatment Editorial Board. Mycosis Fungoides (Including Sézary Syndrome) Treatment (PDQ®): Health Professional Version. PDQ Cancer Information Summaries. 2002:():
[PubMed PMID: 26389288]
[28]
Wain T, Venning VL, Consuegra G, Fernandez-Peñas P, Wells J. Management of cutaneous T-cell lymphomas: Established and emergent therapies. The Australasian journal of dermatology. 2019 Aug:60(3):200-208. doi: 10.1111/ajd.13011. Epub 2019 Feb 26
[PubMed PMID: 30809800]
[29]
Dairi M, Dadban A, Arnault JP, Lok C, Chaby G. Localized mycosis fungoides treated with laser-assisted photodynamic therapy: a case series. Clinical and experimental dermatology. 2019 Dec:44(8):930-932. doi: 10.1111/ced.13936. Epub 2019 Mar 1
[PubMed PMID: 30825216]
Level 2 (mid-level) evidence
[30]
Cho A, Jantschitsch C, Knobler R. Extracorporeal Photopheresis-An Overview. Frontiers in medicine. 2018:5():236. doi: 10.3389/fmed.2018.00236. Epub 2018 Aug 27
[PubMed PMID: 30211164]
Level 3 (low-level) evidence
[31]
Brazzelli V, Bernacca C, Segal A, Barruscotti S, Bolcato V, Michelerio A, Tomasini CF. Photo-photochemotherapy in Juvenile-onset Mycosis Fungoides: A Retrospective Study on 9 Patients. Journal of pediatric hematology/oncology. 2019 Jan:41(1):34-37. doi: 10.1097/MPH.0000000000001277. Epub
[PubMed PMID: 30130275]
Level 2 (mid-level) evidence
[32]
Photiou L, van der Weyden C, McCormack C, Miles Prince H. Systemic Treatment Options for Advanced-Stage Mycosis Fungoides and Sézary Syndrome. Current oncology reports. 2018 Mar 23:20(4):32. doi: 10.1007/s11912-018-0678-x. Epub 2018 Mar 23
[PubMed PMID: 29572582]
[33]
Jang BS, Kim E, Kim IH, Kang HC, Ye SJ. Clinical outcomes and prognostic factors in patients with mycosis fungoides who underwent radiation therapy in a single institution. Radiation oncology journal. 2018 Jun:36(2):153-162. doi: 10.3857/roj.2017.00542. Epub 2018 Jun 29
[PubMed PMID: 29983036]
Level 2 (mid-level) evidence
[34]
Alpdogan O, Kartan S, Johnson W, Sokol K, Porcu P. Systemic therapy of cutaneous T-cell lymphoma (CTCL). Chinese clinical oncology. 2019 Feb:8(1):10. doi: 10.21037/cco.2019.01.02. Epub
[PubMed PMID: 30818958]
[35]
Berg S, Villasenor-Park J, Haun P, Kim EJ. Multidisciplinary Management of Mycosis Fungoides/Sézary Syndrome. Current hematologic malignancy reports. 2017 Jun:12(3):234-243. doi: 10.1007/s11899-017-0387-9. Epub
[PubMed PMID: 28540671]
[36]
Olisova OY, Grekova EV, Varshavsky VA, Gorenkova LG, Alekseeva EA, Zaletaev DV, Sydikov AA. [Current possibilities of the differential diagnosis of plaque parapsoriasis and the early stages of mycosis fungoides]. Arkhiv patologii. 2019:81(1):9-17. doi: 10.17116/patol2019810119. Epub
[PubMed PMID: 30830099]
[37]
Olsen E, Vonderheid E, Pimpinelli N, Willemze R, Kim Y, Knobler R, Zackheim H, Duvic M, Estrach T, Lamberg S, Wood G, Dummer R, Ranki A, Burg G, Heald P, Pittelkow M, Bernengo MG, Sterry W, Laroche L, Trautinger F, Whittaker S, ISCL/EORTC. Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood. 2007 Sep 15:110(6):1713-22
[PubMed PMID: 17540844]
[38]
O'Brien JS, Manning T, Perera M, Prince HM, Lawrentschuk N. Blueprint unknown: a case for multidisciplinary management of advanced penile mycosis fungoides. The Canadian journal of urology. 2017 Dec:24(6):9139-9144
[PubMed PMID: 29260643]
Level 3 (low-level) evidence
[39]
Lebowitz E, Geller S, Flores E, Pulitzer M, Horwitz S, Moskowitz A, Kheterpal M, Myskowski PL. Survival, disease progression and prognostic factors in elderly patients with mycosis fungoides and Sézary syndrome: a retrospective analysis of 174 patients. Journal of the European Academy of Dermatology and Venereology : JEADV. 2019 Jan:33(1):108-114. doi: 10.1111/jdv.15236. Epub 2018 Sep 25
[PubMed PMID: 30176169]
Level 2 (mid-level) evidence